Clinical Trials Directory

Trials / Unknown

UnknownNCT03936517

Safety and Efficacy of Prednisolone in Adrenal Insufficiency Disease (PRED-AID Study)

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
44 (estimated)
Sponsor
Imperial College London · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

This study compares low-dose prednisolone therapy against standard regimens of hydrocortisone therapy for the treatment of adrenal insufficiency (AI). AI is a condition in which, individuals are unable to sufficiently produce the natural stress hormone, cortisol.

Detailed description

Steroid replacement therapy is vital for the health of patients with adrenal insufficiency (AI), who are unable to produce the natural stress hormone, cortisol. The objectives of steroid replacement therapy are to replace the body's physiological requirements for cortisol without over-replacement and consequent Cushing's syndrome. Equally, under-replacement presents the risk of patients experiencing potentially fatal Addisonian crises. Appropriately replacing a patient's steroid requirement is a significant challenge. Hydrocortisone (HC) is used in the majority of patients with AI in the UK. However, HC has a short duration of action, necessitating dosing 3 times a day. Low-dose prednisolone (PR) is an alternative to HC which needs only once-daily. There have been no studies directly comparing low-dose PR to HC treatment. This is a two-arm, two-period, double-blind, randomised, cross-over study comparing the low dose PR and standard regimens of HC in the treatment of AI.

Conditions

Interventions

TypeNameDescription
DRUGPrednisoloneLow dose prednisolone for the treatment of adrenal insufficiency. Usually administered once daily
DRUGHydrocortisoneStandard regimens of hydrocortisone for the treatment of adrenal insufficiency. Usually administered thrice daily.

Timeline

Start date
2019-07-31
Primary completion
2025-02-01
Completion
2025-02-01
First posted
2019-05-03
Last updated
2023-09-01

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT03936517. Inclusion in this directory is not an endorsement.